A comparative evaluation is made on activity, resistance problems and side effects of nine quinolones. These data and the information on clinical experiences are used to outline the author's view on the present position of these compounds in treatment policies. The following indications seem appropriate: norfloxacin or pipemidic acid in lower urinary tract infection, secondary to nitrofurantoin and sulfonamides; one of the more active quinolones, like ciprofloxacin, in case of therapy failure or multiple resistance; application for gonorrhoea appears attractive, but data on long-term effects and resistance are needed; in antibacterial combinations for selective bowel decontamination. Comparative clinical trials are essential before other indications for quinolones in clinical policies can be defined.